{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:06:03Z","timestamp":1791187563949,"version":"4.1.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2011,10,24]],"date-time":"2011-10-24T00:00:00Z","timestamp":1319414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Cancer"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1038\/nrc3150","type":"journal-article","created":{"date-parts":[[2011,10,24]],"date-time":"2011-10-24T05:35:50Z","timestamp":1319434550000},"page":"813-823","source":"Crossref","is-referenced-by-count":134,"title":["Parkinson's disease and cancer: two wars, one front"],"prefix":"10.1038","volume":"11","author":[{"given":"Michael J.","family":"Devine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9l\u00e8ne","family":"Plun-Favreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas W.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,24]]},"reference":[{"key":"BFnrc3150_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic, J. Parkinson's disease: clinical features and diagnosis. J. Neurol. Neurosurg. Psychiatr. 79, 368\u2013376 (2008).","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"BFnrc3150_CR2","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1001\/jama.1954.02950070008003","volume":"156","author":"LJ Doshay","year":"1954","unstructured":"Doshay, L. J. Problem situations in the treatment of paralysis agitans. J. Am. Med. Assoc. 156, 680\u2013684 (1954).","journal-title":"J. Am. Med. Assoc."},{"key":"BFnrc3150_CR3","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos, M. H. et al. Mutation in the \u03b1-synuclein gene identified in families with Parkinson's disease. Science 276, 2045\u20132047 (1997).","journal-title":"Science"},{"key":"BFnrc3150_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini, M. G. et al. \u03b1-synuclein in Lewy bodies. Nature 388, 839\u2013840 (1997).","journal-title":"Nature"},{"issue":"Suppl. 2","key":"BFnrc3150_CR5","first-page":"II3","volume":"247","author":"H Braak","year":"2000","unstructured":"Braak, H. & Braak, E. Pathoanatomy of Parkinson's disease. J. Neurol. 247 (Suppl. 2), II3\u201310 (2000).","journal-title":"J. Neurol."},{"key":"BFnrc3150_CR6","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ng.485","volume":"41","author":"W Satake","year":"2009","unstructured":"Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nature Genet. 41, 1303\u20131307 (2009).","journal-title":"Nature Genet."},{"key":"BFnrc3150_CR7","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1038\/ng.487","volume":"41","author":"J Simon-Sanchez","year":"2009","unstructured":"Simon-Sanchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genet. 41, 1308\u20131312 (2009).","journal-title":"Nature Genet."},{"key":"BFnrc3150_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neuron.2010.10.014","volume":"68","author":"J Hardy","year":"2010","unstructured":"Hardy, J. Genetic analysis of pathways to Parkinson disease. Neuron 68, 201\u2013206 (2010).","journal-title":"Neuron"},{"key":"BFnrc3150_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646\u2013674 (2011).","journal-title":"Cell"},{"key":"BFnrc3150_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nature05610","volume":"446","author":"C Greenman","year":"2007","unstructured":"Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153\u2013158 (2007).","journal-title":"Nature"},{"key":"BFnrc3150_CR11","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nature05291","volume":"443","author":"DC Rubinsztein","year":"2006","unstructured":"Rubinsztein, D. C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780\u2013786 (2006).","journal-title":"Nature"},{"key":"BFnrc3150_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00441-004-0954-y","volume":"318","author":"JB Schulz","year":"2004","unstructured":"Schulz, J. B. & Falkenburger, B. H. Neuronal pathology in Parkinson's disease. Cell Tissue Res. 318, 135\u2013147 (2004).","journal-title":"Cell Tissue Res."},{"key":"BFnrc3150_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1006\/exnr.2002.8050","volume":"179","author":"KS McNaught","year":"2003","unstructured":"McNaught, K. S., Belizaire, R., Isacson, O., Jenner, P. & Olanow, C. W. Altered proteasomal function in sporadic Parkinson's disease. Exp. Neurol. 179, 38\u201346 (2003).","journal-title":"Exp. Neurol."},{"key":"BFnrc3150_CR14","first-page":"67","volume":"232","author":"MD Scott","year":"2003","unstructured":"Scott, M. D. & Frydman, J. Aberrant protein folding as the molecular basis of cancer. Methods Mol. Biol. 232, 67\u201376 (2003).","journal-title":"Methods Mol. Biol."},{"key":"BFnrc3150_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ccr.2007.10.001","volume":"12","author":"T Soussi","year":"2007","unstructured":"Soussi, T. & Wiman, K. G. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 12, 303\u2013312 (2007).","journal-title":"Cancer Cell"},{"key":"BFnrc3150_CR16","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1016\/j.febslet.2011.05.022","volume":"585","author":"CL Brooks","year":"2011","unstructured":"Brooks, C. L. & Gu, W. p53 regulation by ubiquitin. FEBS Lett. 585, 2803\u20132809 (2011).","journal-title":"FEBS Lett."},{"key":"BFnrc3150_CR17","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1073\/pnas.80.9.2613","volume":"80","author":"V Rotter","year":"1983","unstructured":"Rotter, V. p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proc. Natl Acad. Sci. USA 80, 2613\u20132617 (1983).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR18","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1073\/pnas.89.15.7262","volume":"89","author":"UM Moll","year":"1992","unstructured":"Moll, U. M., Riou, G. & Levine, A. J. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc. Natl Acad. Sci. USA 89, 7262\u20137266 (1992).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR19","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1002\/j.1460-2075.1990.tb08279.x","volume":"9","author":"JV Gannon","year":"1990","unstructured":"Gannon, J. V., Greaves, R., Iggo, R. & Lane, D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9, 1595\u20131602 (1990).","journal-title":"EMBO J."},{"key":"BFnrc3150_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nchembio.546","volume":"7","author":"J Xu","year":"2011","unstructured":"Xu, J. et al. Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nature Chem. Biol. 7, 285\u2013295 (2011).","journal-title":"Nature Chem. Biol."},{"key":"BFnrc3150_CR21","first-page":"97","volume":"37","author":"CH Kim","year":"2010","unstructured":"Kim, C. H. et al. Role of reactive oxygen species-dependent protein aggregation in metabolic stress-induced necrosis. Int. J. Oncol. 37, 97\u2013102 (2010).","journal-title":"Int. J. Oncol."},{"key":"BFnrc3150_CR22","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/33416","volume":"392","author":"T Kitada","year":"1998","unstructured":"Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605\u2013608 (1998).","journal-title":"Nature"},{"key":"BFnrc3150_CR23","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/77060","volume":"25","author":"H Shimura","year":"2000","unstructured":"Shimura, H. et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genet. 25, 302\u2013305 (2000).","journal-title":"Nature Genet."},{"key":"BFnrc3150_CR24","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbamcr.2004.09.026","volume":"1695","author":"K Tanaka","year":"2004","unstructured":"Tanaka, K., Suzuki, T., Hattori, N. & Mizuno, Y. Ubiquitin, proteasome and parkin. Biochim. Biophys. Acta 1695, 235\u2013247 (2004).","journal-title":"Biochim. Biophys. Acta"},{"key":"BFnrc3150_CR25","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1126\/science.1093891","volume":"304","author":"KK Chung","year":"2004","unstructured":"Chung, K. K. et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 304, 1328\u20131331 (2004).","journal-title":"Science"},{"key":"BFnrc3150_CR26","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/nm1314","volume":"11","author":"MJ LaVoie","year":"2005","unstructured":"LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G. & Selkoe, D. J. Dopamine covalently modifies and functionally inactivates parkin. Nature Med. 11, 1214\u20131221 (2005).","journal-title":"Nature Med."},{"key":"BFnrc3150_CR27","doi-asserted-by":"publisher","first-page":"47199","DOI":"10.1074\/jbc.M306769200","volume":"278","author":"KF Winklhofer","year":"2003","unstructured":"Winklhofer, K. F., Henn, I. H., Kay-Jackson, P. C., Heller, U. & Tatzelt, J. Inactivation of parkin by oxidative stress and C-terminal truncations: a protective role of molecular chaperones. J. Biol. Chem. 278, 47199\u201347208 (2003).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3150_CR28","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1073\/pnas.0913485107","volume":"107","author":"E Ziviani","year":"2010","unstructured":"Ziviani, E., Tao, R. N. & Whitworth, A. J. Drosophila parkin requires PINK1 for mitochondrial translocation and ubiquitinates mitofusin. Proc. Natl Acad. Sci. USA 107, 5018\u20135023 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR29","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.1093\/hmg\/ddq419","volume":"19","author":"ME Gegg","year":"2010","unstructured":"Gegg, M. E. et al. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1\/parkin-dependent manner upon induction of mitophagy. Hum. Mol. Genet. 19, 4861\u20134870 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrc3150_CR30","doi-asserted-by":"publisher","first-page":"e16746","DOI":"10.1371\/journal.pone.0016746","volume":"6","author":"A Rakovic","year":"2011","unstructured":"Rakovic, A. et al. Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts. PLoS ONE 6, e16746 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrc3150_CR31","first-page":"5586","volume":"56","author":"S Saito","year":"1996","unstructured":"Saito, S. et al. Definition of a commonly deleted region in ovarian cancers to a 300-kb segment of chromosome 6q27. Cancer Res. 56, 5586\u20135589 (1996).","journal-title":"Cancer Res."},{"key":"BFnrc3150_CR32","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/bjc.1995.132","volume":"71","author":"V Orphanos","year":"1995","unstructured":"Orphanos, V. et al. Allelic imbalance of chromosome 6q in ovarian tumours. Br. J. Cancer 71, 666\u2013669 (1995).","journal-title":"Br. J. Cancer"},{"key":"BFnrc3150_CR33","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1038\/sj.onc.1203437","volume":"19","author":"FM Kong","year":"2000","unstructured":"Kong, F. M., Anscher, M. S., Washington, M. K., Killian, J. K. & Jirtle, R. L. M6P\/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 19, 1572\u20131578 (2000).","journal-title":"Oncogene"},{"key":"BFnrc3150_CR34","first-page":"1331","volume":"54","author":"M Negrini","year":"1994","unstructured":"Negrini, M. et al. Suppression of tumorigenicity of breast cancer cells by microcell-mediated chromosome transfer: studies on chromosomes 6 and 11. Cancer Res. 54, 1331\u20131336 (1994).","journal-title":"Cancer Res."},{"key":"BFnrc3150_CR35","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1073\/pnas.0931262100","volume":"100","author":"R Cesari","year":"2003","unstructured":"Cesari, R. et al. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc. Natl Acad. Sci. USA 100, 5956\u20135961 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/ng.491","volume":"42","author":"S Veeriah","year":"2010","unstructured":"Veeriah, S. et al. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nature Genet. 42, 77\u201382 (2010).","journal-title":"Nature Genet."},{"key":"BFnrc3150_CR37","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/S1474-4422(07)70174-6","volume":"6","author":"C Klein","year":"2007","unstructured":"Klein, C., Lohmann-Hedrich, K., Rogaeva, E., Schlossmacher, M. G. & Lang, A. E. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol. 6, 652\u2013662 (2007).","journal-title":"Lancet Neurol."},{"key":"BFnrc3150_CR38","doi-asserted-by":"publisher","first-page":"29231","DOI":"10.1074\/jbc.M110.108241","volume":"285","author":"SP Tay","year":"2010","unstructured":"Tay, S. P. et al. Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J. Biol. Chem. 285, 29231\u201329238 (2010).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3150_CR39","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ncb1981","volume":"11","author":"CA da Costa","year":"2009","unstructured":"da Costa, C. A. et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nature Cell Biol. 11, 1370\u20131375 (2009).","journal-title":"Nature Cell Biol."},{"key":"BFnrc3150_CR40","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1158\/0008-5472.CAN-07-5989","volume":"68","author":"A Rodriguez-Gonzalez","year":"2008","unstructured":"Rodriguez-Gonzalez, A. et al. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res. 68, 2557\u20132560 (2008).","journal-title":"Cancer Res."},{"key":"BFnrc3150_CR41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4161\/auto.5172","volume":"4","author":"JA Olzmann","year":"2008","unstructured":"Olzmann, J. A. & Chin, L. S. Parkin-mediated K63-linked polyubiquitination: a signal for targeting misfolded proteins to the aggresome-autophagy pathway. Autophagy 4, 85\u201387 (2008).","journal-title":"Autophagy"},{"key":"BFnrc3150_CR42","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0092-8674(03)00939-5","volume":"115","author":"Y Kawaguchi","year":"2003","unstructured":"Kawaguchi, Y. et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115, 727\u2013738 (2003).","journal-title":"Cell"},{"key":"BFnrc3150_CR43","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1523\/JNEUROSCI.0860-10.2010","volume":"30","author":"M Tang","year":"2010","unstructured":"Tang, M. et al. Interactions of Wnt\/\u03b2-catenin signaling and sonic hedgehog regulate the neurogenesis of ventral midbrain dopamine neurons. J. Neurosci. 30, 9280\u20139291 (2010).","journal-title":"J. Neurosci."},{"key":"BFnrc3150_CR44","doi-asserted-by":"publisher","first-page":"9658","DOI":"10.1523\/JNEUROSCI.1773-05.2005","volume":"25","author":"S Cicero","year":"2005","unstructured":"Cicero, S. & Herrup, K. Cyclin-dependent kinase 5 is essential for neuronal cell cycle arrest and differentiation. J. Neurosci. 25, 9658\u20139668 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrc3150_CR45","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1038\/sj.cdd.4401108","volume":"9","author":"MD Nguyen","year":"2002","unstructured":"Nguyen, M. D., Mushynski, W. E. & Julien, J. P. Cycling at the interface between neurodevelopment and neurodegeneration. Cell Death Differ. 9, 1294\u20131306 (2002).","journal-title":"Cell Death Differ."},{"key":"BFnrc3150_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/S0197-4580(03)00037-X","volume":"25","author":"DK Simon","year":"2004","unstructured":"Simon, D. K. et al. Somatic mitochondrial DNA mutations in cortex and substantia nigra in aging and Parkinson's disease. Neurobiol. Aging 25, 71\u201381 (2004).","journal-title":"Neurobiol. Aging"},{"key":"BFnrc3150_CR47","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/ng1769","volume":"38","author":"A Bender","year":"2006","unstructured":"Bender, A. et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nature Genet. 38, 515\u2013517 (2006).","journal-title":"Nature Genet."},{"key":"BFnrc3150_CR48","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1016\/j.dnarep.2008.03.012","volume":"7","author":"JL Yang","year":"2008","unstructured":"Yang, J. L., Weissman, L., Bohr, V. A. & Mattson, M. P. Mitochondrial DNA damage and repair in neurodegenerative disorders. DNA Repair 7, 1110\u20131120 (2008).","journal-title":"DNA Repair"},{"key":"BFnrc3150_CR49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.gep.2010.09.004","volume":"11","author":"Y Ikeda","year":"2011","unstructured":"Ikeda, Y., Matsunaga, Y., Takiguchi, M. & Ikeda, M. A. Expression of cyclin E in postmitotic neurons during development and in the adult mouse brain. Gene Expr. Patterns 11, 64\u201371 (2011).","journal-title":"Gene Expr. Patterns"},{"key":"BFnrc3150_CR50","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0896-6273(03)00084-9","volume":"37","author":"JF Staropoli","year":"2003","unstructured":"Staropoli, J. F. et al. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37, 735\u2013749 (2003).","journal-title":"Neuron"},{"key":"BFnrc3150_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.pneurobio.2011.03.006","volume":"94","author":"JP Lopes","year":"2011","unstructured":"Lopes, J. P. & Agostinho, P. Cdk5: multitasking between physiological and pathological conditions. Prog. Neurobiol. 94, 49\u201363 (2011).","journal-title":"Prog. Neurobiol."},{"key":"BFnrc3150_CR52","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1073\/pnas.0611671104","volume":"104","author":"GU Hoglinger","year":"2007","unstructured":"Hoglinger, G. U. et al. The pRb\/E2F cell-cycle pathway mediates cell death in Parkinson's disease. Proc. Natl Acad. Sci. USA 104, 3585\u20133590 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR53","doi-asserted-by":"publisher","first-page":"7968","DOI":"10.1523\/JNEUROSCI.2172-05.2005","volume":"25","author":"HS Ko","year":"2005","unstructured":"Ko, H. S. et al. Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38\/JTV-1, leads to catecholaminergic cell death. J. Neurosci. 25, 7968\u20137978 (2005).","journal-title":"J. Neurosci."},{"key":"BFnrc3150_CR54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1212\/01.wnl.0000338144.10967.2b","volume":"72","author":"A Di Fonzo","year":"2009","unstructured":"Di Fonzo, A. et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72, 240\u2013245 (2009).","journal-title":"Neurology"},{"key":"BFnrc3150_CR55","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S1097-2765(02)00538-5","volume":"9","author":"PK Jackson","year":"2002","unstructured":"Jackson, P. K. & Eldridge, A. G. The SCF ubiquitin ligase: an extended look. Mol. Cell 9, 923\u2013925 (2002).","journal-title":"Mol. Cell"},{"key":"BFnrc3150_CR56","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1038\/sj.emboj.7600775","volume":"24","author":"H Laman","year":"2005","unstructured":"Laman, H. et al. Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D\/cdk6. EMBO J. 24, 3104\u20133116 (2005).","journal-title":"EMBO J."},{"key":"BFnrc3150_CR57","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.bbrc.2006.02.061","volume":"342","author":"YF Chang","year":"2006","unstructured":"Chang, Y. F., Cheng, C. M., Chang, L. K., Jong, Y. J. & Yuo, C. Y. The F-box protein Fbxo7 interacts with human inhibitor of apoptosis protein cIAP1 and promotes cIAP1 ubiquitination. Biochem. Biophys. Res. Commun. 342, 1022\u20131026 (2006).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrc3150_CR58","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1126\/science.1077209","volume":"299","author":"V Bonifati","year":"2003","unstructured":"Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256\u2013259 (2003).","journal-title":"Science"},{"key":"BFnrc3150_CR59","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1111\/j.1471-4159.2006.04291.x","volume":"100","author":"S Bretaud","year":"2007","unstructured":"Bretaud, S., Allen, C., Ingham, P. W. & Bandmann, O. p53-dependent neuronal cell death in a DJ-1-deficient zebrafish model of Parkinson's disease. J. Neurochem. 100, 1626\u20131635 (2007).","journal-title":"J. Neurochem."},{"key":"BFnrc3150_CR60","doi-asserted-by":"publisher","first-page":"4022","DOI":"10.1074\/jbc.M707176200","volume":"283","author":"J Fan","year":"2008","unstructured":"Fan, J. et al. DJ-1 decreases Bax expression through repressing p53 transcriptional activity. J. Biol. Chem. 283, 4022\u20134030 (2008).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3150_CR61","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/cdd.2009.116","volume":"17","author":"E Giaime","year":"2010","unstructured":"Giaime, E. et al. Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6. Cell Death Differ. 17, 158\u2013169 (2010).","journal-title":"Cell Death Differ."},{"key":"BFnrc3150_CR62","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","volume":"7","author":"DG Healy","year":"2008","unstructured":"Healy, D. G. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7, 583\u2013590 (2008).","journal-title":"Lancet Neurol."},{"key":"BFnrc3150_CR63","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature02871","volume":"431","author":"V Ambros","year":"2004","unstructured":"Ambros, V. The functions of animal microRNAs. Nature 431, 350\u2013355 (2004).","journal-title":"Nature"},{"key":"BFnrc3150_CR64","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/nature09191","volume":"466","author":"S Gehrke","year":"2010","unstructured":"Gehrke, S., Imai, Y., Sokol, N. & Lu, B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 466, 637\u2013641 (2010).","journal-title":"Nature"},{"key":"BFnrc3150_CR65","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1038\/nrd3179","volume":"9","author":"R Garzon","year":"2010","unstructured":"Garzon, R., Marcucci, G. & Croce, C. M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nature Rev. Drug Discov. 9, 775\u2013789 (2010).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3150_CR66","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1126\/science.6823561","volume":"219","author":"JW Langston","year":"1983","unstructured":"Langston, J. W., Ballard, P., Tetrud, J. W. & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979\u2013980 (1983).","journal-title":"Science"},{"key":"BFnrc3150_CR67","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/S0140-6736(89)92366-0","volume":"1","author":"AH Schapira","year":"1989","unstructured":"Schapira, A. H. et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1, 1269 (1989).","journal-title":"Lancet"},{"key":"BFnrc3150_CR68","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/81834","volume":"3","author":"R Betarbet","year":"2000","unstructured":"Betarbet, R. et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neurosci. 3, 1301\u20131306 (2000).","journal-title":"Nature Neurosci."},{"key":"BFnrc3150_CR69","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg, O. On the origin of cancer cells. Science 123, 309\u2013314 (1956).","journal-title":"Science"},{"key":"BFnrc3150_CR70","doi-asserted-by":"publisher","first-page":"466","DOI":"10.4161\/auto.7.5.14731","volume":"7","author":"R Gargini","year":"2011","unstructured":"Gargini, R., Garcia-Escudero, V. & Izquierdo, M. Therapy mediated by mitophagy abrogates tumor progression. Autophagy 7, 466\u2013476 (2011).","journal-title":"Autophagy"},{"key":"BFnrc3150_CR71","doi-asserted-by":"crossref","unstructured":"Kim, J. H. et al. Involvement of mitophagy in oncogenic K-Ras-induced transformation: overcoming a cellular energy deficit from glucose deficiency. Autophagy 7 (2011).","DOI":"10.4161\/auto.7.10.16643"},{"key":"BFnrc3150_CR72","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1126\/science.1096284","volume":"304","author":"EM Valente","year":"2004","unstructured":"Valente, E. M. et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304, 1158\u20131160 (2004).","journal-title":"Science"},{"key":"BFnrc3150_CR73","doi-asserted-by":"publisher","first-page":"e172","DOI":"10.1371\/journal.pbio.0050172","volume":"5","author":"JW Pridgeon","year":"2007","unstructured":"Pridgeon, J. W., Olzmann, J. A., Chin, L. S. & Li, L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 5, e172 (2007).","journal-title":"PLoS Biol."},{"key":"BFnrc3150_CR74","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1038\/nature04788","volume":"441","author":"J Park","year":"2006","unstructured":"Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157\u20131161 (2006).","journal-title":"Nature"},{"key":"BFnrc3150_CR75","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1038\/nature04779","volume":"441","author":"IE Clark","year":"2006","unstructured":"Clark, I. E. et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162\u20131166 (2006).","journal-title":"Nature"},{"key":"BFnrc3150_CR76","doi-asserted-by":"publisher","first-page":"12413","DOI":"10.1523\/JNEUROSCI.0719-07.2007","volume":"27","author":"N Exner","year":"2007","unstructured":"Exner, N. et al. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. J. Neurosci. 27, 12413\u201312418 (2007).","journal-title":"J. Neurosci."},{"key":"BFnrc3150_CR77","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1083\/jcb.200809125","volume":"183","author":"D Narendra","year":"2008","unstructured":"Narendra, D., Tanaka, A., Suen, D. F. & Youle, R. J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795\u2013803 (2008).","journal-title":"J. Cell Biol."},{"key":"BFnrc3150_CR78","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1158\/0008-5472.CAN-10-2836","volume":"71","author":"SA Martin","year":"2011","unstructured":"Martin, S. A., Hewish, M., Sims, D., Lord, C. J. & Ashworth, A. Parallel high-throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair-deficient cancers. Cancer Res. 71, 1836\u20131848 (2011).","journal-title":"Cancer Res."},{"key":"BFnrc3150_CR79","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1073\/pnas.0501282102","volume":"102","author":"RH Kim","year":"2005","unstructured":"Kim, R. H. et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl Acad. Sci. USA 102, 5215\u20135220 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR80","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1371\/journal.pbio.0020362","volume":"2","author":"S Shendelman","year":"2004","unstructured":"Shendelman, S., Jonason, A., Martinat, C., Leete, T. & Abeliovich, A. DJ-1 is a redox-dependent molecular chaperone that inhibits \u03b1-synuclein aggregate formation. PLoS Biol. 2, e362 (2004).","journal-title":"PLoS Biol."},{"key":"BFnrc3150_CR81","doi-asserted-by":"publisher","first-page":"15091","DOI":"10.1073\/pnas.0607260103","volume":"103","author":"CM Clements","year":"2006","unstructured":"Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W. & Ting, J. P. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl Acad. Sci. USA 103, 15091\u201315096 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR82","doi-asserted-by":"publisher","first-page":"10244","DOI":"10.1073\/pnas.0708518105","volume":"105","author":"MP van der Brug","year":"2008","unstructured":"van der Brug, M. P. et al. RNA binding activity of the recessive parkinsonism protein DJ-1 supports involvement in multiple cellular pathways. Proc. Natl Acad. Sci. USA 105, 10244\u201310249 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR83","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1093\/hmg\/ddq288","volume":"19","author":"I Irrcher","year":"2010","unstructured":"Irrcher, I. et al. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum. Mol. Genet. 19, 3734\u20133746 (2010).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrc3150_CR84","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1038\/emboj.2010.223","volume":"29","author":"F Kamp","year":"2010","unstructured":"Kamp, F. et al. Inhibition of mitochondrial fusion by \u03b1-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 29, 3571\u20133589 (2010).","journal-title":"EMBO J."},{"key":"BFnrc3150_CR85","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1172\/JCI37617","volume":"119","author":"H Xiong","year":"2009","unstructured":"Xiong, H. et al. Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation. J. Clin. Invest. 119, 650\u2013660 (2009).","journal-title":"J. Clin. Invest."},{"key":"BFnrc3150_CR86","doi-asserted-by":"publisher","first-page":"10793","DOI":"10.1073\/pnas.0602493103","volume":"103","author":"Y Yang","year":"2006","unstructured":"Yang, Y. et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl Acad. Sci. USA 103, 10793\u201310798 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR87","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1006\/bbrc.1997.6132","volume":"231","author":"D Nagakubo","year":"1997","unstructured":"Nagakubo, D. et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem. Biophys. Res. Commun. 231, 509\u2013513 (1997).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrc3150_CR88","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay, N. & Sonenberg, N. Upstream and downstream of mTOR. Genes Dev. 18, 1926\u20131945 (2004).","journal-title":"Genes Dev."},{"key":"BFnrc3150_CR89","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrd2926","volume":"8","author":"P Liu","year":"2009","unstructured":"Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Rev. Drug Discov. 8, 627\u2013644 (2009).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3150_CR90","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/humu.21038","volume":"30","author":"C Paisan-Ruiz","year":"2009","unstructured":"Paisan-Ruiz, C. LRRK2 gene variation and its contribution to Parkinson disease. Hum. Mutat. 30, 1153\u20131160 (2009).","journal-title":"Hum. Mutat."},{"key":"BFnrc3150_CR91","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nrn2935","volume":"11","author":"MR Cookson","year":"2010","unstructured":"Cookson, M. R. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nature Rev. Neurosci. 11, 791\u2013797 (2010).","journal-title":"Nature Rev. Neurosci."},{"key":"BFnrc3150_CR92","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1038\/emboj.2008.163","volume":"27","author":"Y Imai","year":"2008","unstructured":"Imai, Y. et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 27, 2432\u20132443 (2008).","journal-title":"EMBO J."},{"key":"BFnrc3150_CR93","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nature05603","volume":"445","author":"P Syntichaki","year":"2007","unstructured":"Syntichaki, P., Troulinaki, K. & Tavernarakis, N. eIF4E function in somatic cells modulates ageing in Caenorhabditis elegans. Nature 445, 922\u2013926 (2007).","journal-title":"Nature"},{"key":"BFnrc3150_CR94","doi-asserted-by":"publisher","first-page":"e8730","DOI":"10.1371\/journal.pone.0008730","volume":"5","author":"A Kumar","year":"2010","unstructured":"Kumar, A. et al. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS ONE 5, e8730 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrc3150_CR95","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.febslet.2011.05.044","volume":"585","author":"E Ohta","year":"2011","unstructured":"Ohta, E., Kawakami, F., Kubo, M. & Obata, F. LRRK2 directly phosphorylates Akt1 as a possible physiological substrate: impairment of the kinase activity by Parkinson's disease-associated mutations. FEBS Lett. 585, 2165\u20132170 (2011).","journal-title":"FEBS Lett."},{"key":"BFnrc3150_CR96","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1073\/pnas.1012500108","volume":"108","author":"BD Looyenga","year":"2011","unstructured":"Looyenga, B. D. et al. Chromosomal amplification of leucine-rich repeat kinase-2 (LRRK2) is required for oncogenic MET signaling in papillary renal and thyroid carcinomas. Proc. Natl Acad. Sci. USA 108, 1439\u20131444 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR97","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1074\/jbc.M309999200","volume":"279","author":"JF Gera","year":"2004","unstructured":"Gera, J. F. et al. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J. Biol. Chem. 279, 2737\u20132746 (2004).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3150_CR98","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nn.2372","volume":"12","author":"LS Tain","year":"2009","unstructured":"Tain, L. S. et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nature Neurosci. 12, 1129\u20131135 (2009).","journal-title":"Nature Neurosci."},{"key":"BFnrc3150_CR99","doi-asserted-by":"publisher","first-page":"7182","DOI":"10.1074\/jbc.M110.179390","volume":"286","author":"H Murata","year":"2011","unstructured":"Murata, H. et al. A new cytosolic pathway from a Parkinson disease-associated kinase, BRPK\/PINK1: activation of AKT via mTORC2. J. Biol. Chem. 286, 7182\u20137189 (2011).","journal-title":"J. Biol. Chem."},{"key":"BFnrc3150_CR100","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1038\/sj.onc.1204608","volume":"20","author":"M Unoki","year":"2001","unstructured":"Unoki, M. & Nakamura, Y. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20, 4457\u20134465 (2001).","journal-title":"Oncogene"},{"key":"BFnrc3150_CR101","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/ng0597-64","volume":"16","author":"D Liaw","year":"1997","unstructured":"Liaw, D. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nature Genet. 16, 64\u201367 (1997).","journal-title":"Nature Genet."},{"key":"BFnrc3150_CR102","first-page":"6928","volume":"63","author":"JP MacKeigan","year":"2003","unstructured":"MacKeigan, J. P. et al. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS\/DJ-1 and RhoGDI\u03b1. Cancer Res. 63, 6928\u20136934 (2003).","journal-title":"Cancer Res."},{"key":"BFnrc3150_CR103","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccr.2005.02.010","volume":"7","author":"RH Kim","year":"2005","unstructured":"Kim, R. H. et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7, 263\u2013273 (2005).","journal-title":"Cancer Cell"},{"key":"BFnrc3150_CR104","doi-asserted-by":"publisher","first-page":"13670","DOI":"10.1073\/pnas.0504610102","volume":"102","author":"Y Yang","year":"2005","unstructured":"Yang, Y. et al. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase\/Akt signaling. Proc. Natl Acad. Sci. USA 102, 13670\u201313675 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR105","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1073\/pnas.0914876107","volume":"107","author":"H Aleyasin","year":"2010","unstructured":"Aleyasin, H. et al. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc. Natl Acad. Sci. USA 107, 3186\u20133191 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR106","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. Cell 141, 39\u201351 (2010).","journal-title":"Cell"},{"key":"BFnrc3150_CR107","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity, inflammation, and cancer. Cell 140, 883\u2013899 (2010).","journal-title":"Cell"},{"key":"BFnrc3150_CR108","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1126\/science.1589760","volume":"256","author":"E Beutler","year":"1992","unstructured":"Beutler, E. Gaucher disease: new molecular approaches to diagnosis and treatment. Science 256, 794\u2013799 (1992).","journal-title":"Science"},{"key":"BFnrc3150_CR109","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/1097-0142(19930701)72:1<219::AID-CNCR2820720139>3.0.CO;2-Y","volume":"72","author":"A Shiran","year":"1993","unstructured":"Shiran, A., Brenner, B., Laor, A. & Tatarsky, I. Increased risk of cancer in patients with Gaucher disease. Cancer 72, 219\u2013224 (1993).","journal-title":"Cancer"},{"key":"BFnrc3150_CR110","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bcmd.2005.08.004","volume":"36","author":"M de Fost","year":"2006","unstructured":"de Fost, M. et al. Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol. Dis. 36, 53\u201358 (2006).","journal-title":"Blood Cells Mol. Dis."},{"key":"BFnrc3150_CR111","first-page":"388","volume":"106","author":"Y Shoenfeld","year":"1982","unstructured":"Shoenfeld, Y. et al. Gaucher's disease: a disease with chronic stimulation of the immune system. Arch. Pathol. Lab. Med. 106, 388\u2013391 (1982).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"BFnrc3150_CR112","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/qjmed\/90.1.19","volume":"90","author":"MJ Allen","year":"1997","unstructured":"Allen, M. J., Myer, B. J., Khokher, A. M., Rushton, N. & Cox, T. M. Pro-inflammatory cytokines and the pathogenesis of Gaucher's disease: increased release of interleukin-6 and interleukin-10. QJM 90, 19\u201325 (1997).","journal-title":"QJM"},{"key":"BFnrc3150_CR113","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s11910-010-0102-x","volume":"10","author":"A Velayati","year":"2010","unstructured":"Velayati, A., Yu, W. H. & Sidransky, E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr. Neurol. Neurosci. Rep. 10, 190\u2013198 (2010).","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"BFnrc3150_CR114","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/brain\/awp044","volume":"132","author":"J Neumann","year":"2009","unstructured":"Neumann, J. et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 132, 1783\u20131794 (2009).","journal-title":"Brain"},{"key":"BFnrc3150_CR115","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1093\/hmg\/ddi240","volume":"14","author":"I Ron","year":"2005","unstructured":"Ron, I. & Horowitz, M. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity. Hum. Mol. Genet. 14, 2387\u20132398 (2005).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrc3150_CR116","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1126\/science.1101738","volume":"305","author":"AM Cuervo","year":"2004","unstructured":"Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T. & Sulzer, D. Impaired degradation of mutant \u03b1-synuclein by chaperone-mediated autophagy. Science 305, 1292\u20131295 (2004).","journal-title":"Science"},{"key":"BFnrc3150_CR117","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2011.06.001","volume":"146","author":"JR Mazzulli","year":"2011","unstructured":"Mazzulli, J. R. et al. Gaucher disease glucocerebrosidase and \u03b1-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146, 37\u201352 (2011).","journal-title":"Cell"},{"key":"BFnrc3150_CR118","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.neuro.2009.06.009","volume":"30","author":"AB Manning-Bog","year":"2009","unstructured":"Manning-Bog, A. B., Schule, B. & Langston, J. W. \u03b1-synuclein-glucocerebrosidase interactions in pharmacological Gaucher models: a biological link between Gaucher disease and parkinsonism. Neurotoxicology 30, 1127\u20131132 (2009).","journal-title":"Neurotoxicology"},{"key":"BFnrc3150_CR119","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1212\/WNL.38.8.1285","volume":"38","author":"PL McGeer","year":"1988","unstructured":"McGeer, P. L., Itagaki, S., Boyes, B. E. & McGeer, E. G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38, 1285\u20131291 (1988).","journal-title":"Neurology"},{"key":"BFnrc3150_CR120","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1111\/j.1460-9568.2003.03014.x","volume":"18","author":"AM Depino","year":"2003","unstructured":"Depino, A. M. et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. 18, 2731\u20132742 (2003).","journal-title":"Eur. J. Neurosci."},{"key":"BFnrc3150_CR121","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1038\/nature09788","volume":"472","author":"MA Burguillos","year":"2011","unstructured":"Burguillos, M. A. et al. Caspase signalling controls microglia activation and neurotoxicity. Nature 472, 319\u2013324 (2011).","journal-title":"Nature"},{"key":"BFnrc3150_CR122","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccr.2007.04.011","volume":"11","author":"C Swanton","year":"2007","unstructured":"Swanton, C. et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 11, 498\u2013512 (2007).","journal-title":"Cancer Cell"},{"key":"BFnrc3150_CR123","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/978-3-211-45295-0_40","volume":"70","author":"BH Falkenburger","year":"2006","unstructured":"Falkenburger, B. H. & Schulz, J. B. Limitations of cellular models in Parkinson's disease research. J. Neural Transm. Suppl. 70, 261\u2013268 (2006).","journal-title":"J. Neural Transm. Suppl."},{"key":"BFnrc3150_CR124","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.neuron.2011.05.003","volume":"70","author":"SS Han","year":"2011","unstructured":"Han, S. S., Williams, L. A. & Eggan, K. C. Constructing and deconstructing stem cell models of neurological disease. Neuron 70, 626\u2013644 (2011).","journal-title":"Neuron"},{"key":"BFnrc3150_CR125","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/hmg\/ddh134","volume":"13","author":"JA Beck","year":"2004","unstructured":"Beck, J. A. et al. Somatic and germline mosaicism in sporadic early-onset Alzheimer's disease. Hum. Mol. Genet. 13, 1219\u20131224 (2004).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrc3150_CR126","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(89)90421-2","volume":"2","author":"IF Rowe","year":"1989","unstructured":"Rowe, I. F., Ridler, M. A. & Gibberd, F. B. Presenile dementia associated with mosaic trisomy 21 in a patient with a Down syndrome child. Lancet 2, 229 (1989).","journal-title":"Lancet"},{"key":"BFnrc3150_CR127","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/mds.21537","volume":"22","author":"B Post","year":"2007","unstructured":"Post, B., Merkus, M. P., de Haan, R. J. & Speelman, J. D. Prognostic factors for the progression of Parkinson's disease: a systematic review. Mov. Disord. 22, 1839\u20131851; quiz 1988 (2007).","journal-title":"Mov. Disord."},{"key":"BFnrc3150_CR128","first-page":"3","volume":"16","author":"GR Newell","year":"1989","unstructured":"Newell, G. R., Spitz, M. R. & Sider, J. G. Cancer and age. Semin. Oncol. 16, 3\u20139 (1989).","journal-title":"Semin. Oncol."},{"key":"BFnrc3150_CR129","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1038\/319618a0","volume":"319","author":"W Gilbert","year":"1986","unstructured":"Gilbert, W. Origins of Life: the RNA world. Nature 319, 618 (1986).","journal-title":"Nature"},{"key":"BFnrc3150_CR130","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jama.2010.284","volume":"303","author":"SM Gapstur","year":"2010","unstructured":"Gapstur, S. M. & Thun, M. J. Progress in the war on cancer. JAMA 303, 1084\u20131085 (2010).","journal-title":"JAMA"},{"key":"BFnrc3150_CR131","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.cell.2011.03.026","volume":"145","author":"DA Haber","year":"2011","unstructured":"Haber, D. A., Gray, N. S. & Baselga, J. The evolving war on cancer. Cell 145, 19\u201324 (2011).","journal-title":"Cell"},{"key":"BFnrc3150_CR132","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/ana.410170514","volume":"17","author":"B Jansson","year":"1985","unstructured":"Jansson, B. & Jankovic, J. Low cancer rates among patients with Parkinson's disease. Ann. Neurol. 17, 505\u2013509 (1985).","journal-title":"Ann. Neurol."},{"key":"BFnrc3150_CR133","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1136\/bmj.310.6993.1500","volume":"310","author":"H Moller","year":"1995","unstructured":"Moller, H., Mellemkjaer, L., McLaughlin, J. K. & Olsen, J. H. Occurrence of different cancers in patients with Parkinson's disease. BMJ 310, 1500\u20131501 (1995).","journal-title":"BMJ"},{"key":"BFnrc3150_CR134","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s004150070171","volume":"247","author":"Y Minami","year":"2000","unstructured":"Minami, Y., Yamamoto, R., Nishikouri, M., Fukao, A. & Hisamichi, S. Mortality and cancer incidence in patients with Parkinson's disease. J. Neurol. 247, 429\u2013434 (2000).","journal-title":"J. Neurol."},{"key":"BFnrc3150_CR135","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/ana.10277","volume":"52","author":"MA Hernan","year":"2002","unstructured":"Hernan, M. A., Takkouche, B., Caamano-Isorna, F. & Gestal-Otero, J. J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann. Neurol. 52, 276\u2013284 (2002).","journal-title":"Ann. Neurol."},{"key":"BFnrc3150_CR136","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/sj.bjc.6602279","volume":"92","author":"JH Olsen","year":"2005","unstructured":"Olsen, J. H. et al. Atypical cancer pattern in patients with Parkinson's disease. Br. J. Cancer 92, 201\u2013205 (2005).","journal-title":"Br. J. Cancer"},{"key":"BFnrc3150_CR137","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10552-009-9497-6","volume":"21","author":"A Bajaj","year":"2010","unstructured":"Bajaj, A., Driver, J. A. & Schernhammer, E. S. Parkinson's disease and cancer risk: a systematic review and meta-analysis. Cancer Causes Control 21, 697\u2013707 (2010).","journal-title":"Cancer Causes Control"},{"key":"BFnrc3150_CR138","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1212\/WNL.0b013e31821e554e","volume":"76","author":"R Liu","year":"2011","unstructured":"Liu, R., Gao, X., Lu, Y. & Chen, H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 76, 2002\u20132009 (2011).","journal-title":"Neurology"},{"key":"BFnrc3150_CR139","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1523\/JNEUROSCI.3944-09.2010","volume":"30","author":"C Malagelada","year":"2010","unstructured":"Malagelada, C., Jin, Z. H., Jackson-Lewis, V., Przedborski, S. & Greene, L. A. Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J. Neurosci. 30, 1166\u20131175 (2010).","journal-title":"J. Neurosci."},{"key":"BFnrc3150_CR140","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/nrc2559","volume":"9","author":"J Zhang","year":"2009","unstructured":"Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nature Rev. Cancer 9, 28\u201339 (2009).","journal-title":"Nature Rev. Cancer"},{"key":"BFnrc3150_CR141","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/nm.2199","volume":"16","author":"BD Lee","year":"2010","unstructured":"Lee, B. D. et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nature Med. 16, 998\u20131000 (2010).","journal-title":"Nature Med."},{"key":"BFnrc3150_CR142","doi-asserted-by":"publisher","first-page":"R80","DOI":"10.1186\/bcr2929","volume":"13","author":"BC Nair","year":"2011","unstructured":"Nair, B. C., Vallabhaneni, S., Tekmal, R. R. & Vadlamudi, R. K. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res. 13, R80 (2011).","journal-title":"Breast Cancer Res."},{"key":"BFnrc3150_CR143","doi-asserted-by":"publisher","first-page":"13650","DOI":"10.1073\/pnas.2232515100","volume":"100","author":"PD Smith","year":"2003","unstructured":"Smith, P. D. et al. Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proc. Natl Acad. Sci. USA 100, 13650\u201313655 (2003).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFnrc3150_CR144","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1038\/nrd2999","volume":"8","author":"LK Chico","year":"2009","unstructured":"Chico, L. K., Van Eldik, L. J. & Watterson, D. M. Targeting protein kinases in central nervous system disorders. Nature Rev. Drug Discov. 8, 892\u2013909 (2009).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrc3150_CR145","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1093\/hmg\/10.12.1307","volume":"10","author":"A Sittler","year":"2001","unstructured":"Sittler, A. et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum. Mol. Genet. 10, 1307\u20131315 (2001).","journal-title":"Hum. Mol. Genet."},{"key":"BFnrc3150_CR146","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.bbrc.2004.07.021","volume":"321","author":"PJ McLean","year":"2004","unstructured":"McLean, P. J., Klucken, J., Shin, Y. & Hyman, B. T. Geldanamycin induces Hsp70 and prevents \u03b1-synuclein aggregation and toxicity in vitro. Biochem. Biophys. Res. Commun. 321, 665\u2013669 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFnrc3150_CR147","doi-asserted-by":"publisher","first-page":"e8753","DOI":"10.1371\/journal.pone.0008753","volume":"5","author":"M Riedel","year":"2010","unstructured":"Riedel, M., Goldbaum, O., Schwarz, L., Schmitt, S. & Richter-Landsberg, C. 17-AAG induces cytoplasmic \u03b1-synuclein aggregate clearance by induction of autophagy. PLoS ONE 5, e8753 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrc3150_CR148","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/ncb2012","volume":"12","author":"S Geisler","year":"2010","unstructured":"Geisler, S. et al. PINK1\/Parkin-mediated mitophagy is dependent on VDAC1 and p62\/SQSTM1. Nature Cell Biol. 12, 119\u2013131 (2010).","journal-title":"Nature Cell Biol."},{"key":"BFnrc3150_CR149","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00401-007-0332-4","volume":"115","author":"N Pandey","year":"2008","unstructured":"Pandey, N., Strider, J., Nolan, W. C., Yan, S. X. & Galvin, J. E. Curcumin inhibits aggregation of \u03b1-synuclein. Acta Neuropathol. 115, 479\u2013489 (2008).","journal-title":"Acta Neuropathol."},{"key":"BFnrc3150_CR150","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/PL00007419","volume":"99","author":"M Kawashima","year":"2000","unstructured":"Kawashima, M., Suzuki, S. O., Doh-ura, K. & Iwaki, T. \u03b1-Synuclein is expressed in a variety of brain tumors showing neuronal differentiation. Acta Neuropathol. 99, 154\u2013160 (2000).","journal-title":"Acta Neuropathol."},{"key":"BFnrc3150_CR151","doi-asserted-by":"publisher","first-page":"e10481","DOI":"10.1371\/journal.pone.0010481","volume":"5","author":"Y Matsuo","year":"2010","unstructured":"Matsuo, Y. & Kamitani, T. Parkinson's disease-related protein, \u03b1-synuclein, in malignant melanoma. PLoS ONE 5, e10481 (2010).","journal-title":"PLoS ONE"},{"key":"BFnrc3150_CR152","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2154::AID-CNCR23>3.0.CO;2-9","volume":"88","author":"W Bruening","year":"2000","unstructured":"Bruening, W. et al. Synucleins are expressed in the majority of breast and ovarian carcinomas and in preneoplastic lesions of the ovary. Cancer 88, 2154\u20132163 (2000).","journal-title":"Cancer"},{"key":"BFnrc3150_CR153","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1158\/1078-0432.CCR-09-3178","volume":"16","author":"L Li","year":"2010","unstructured":"Li, L. et al. The tumor suppressor UCHL1 forms a complex with p53\/MDM2\/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin. Cancer Res. 16, 2949\u20132958 (2010).","journal-title":"Clin. Cancer Res."},{"key":"BFnrc3150_CR154","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/ijc.22025","volume":"119","author":"E Okochi-Takada","year":"2006","unstructured":"Okochi-Takada, E. et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int. J. Cancer 119, 1338\u20131344 (2006).","journal-title":"Int. J. Cancer"},{"key":"BFnrc3150_CR155","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.juro.2008.02.044","volume":"180","author":"I Kagara","year":"2008","unstructured":"Kagara, I. et al. CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J. Urol. 180, 343\u2013351 (2008).","journal-title":"J. Urol."},{"key":"BFnrc3150_CR156","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/jcb.20159","volume":"92","author":"Y Hod","year":"2004","unstructured":"Hod, Y. Differential control of apoptosis by DJ-1 in prostate benign and cancer cells. J. Cell. Biochem. 92, 1221\u20131233 (2004).","journal-title":"J. Cell. Biochem."},{"key":"BFnrc3150_CR157","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1176\/jnp.14.2.223","volume":"14","author":"J Parkinson","year":"2002","unstructured":"Parkinson, J. An essay on the shaking palsy. 1817. J. Neuropsychiatry Clin. Neurosci. 14, 223\u2013236; discussion 222 (2002).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"BFnrc3150_CR158","first-page":"920","volume-title":"Handbuch der Neurologie","author":"FH Lewy","year":"1912","unstructured":"Lewy, F. H. in Handbuch der Neurologie (ed. Lewandowsky, M.) 920\u2013933 (Springer, Berlin, 1912)."},{"key":"BFnrc3150_CR159","volume-title":"Contribution a l'etude de l'anatomie pathologique du locus niger de Soemmering avec quelques deductions relatives a la athogenie des troubles du tonus musculaire et de la maladie de Parkinson","author":"C Tretiakoff","year":"1919","unstructured":"Tretiakoff, C. Contribution a l'etude de l'anatomie pathologique du locus niger de Soemmering avec quelques deductions relatives a la athogenie des troubles du tonus musculaire et de la maladie de Parkinson (Jouve and Co, Paris, 1919)."},{"key":"BFnrc3150_CR160","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1038\/1801200a0","volume":"180","author":"A Carlsson","year":"1957","unstructured":"Carlsson, A., Lindqvist, M. & Magnusson, T. 3, 4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180, 1200 (1957).","journal-title":"Nature"},{"key":"BFnrc3150_CR161","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1007\/BF01485901","volume":"38","author":"H Ehringer","year":"1960","unstructured":"Ehringer, H. & Hornykiewicz, O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin. Wochenschr. 38, 1236\u20131239 (1960).","journal-title":"Klin. Wochenschr."},{"key":"BFnrc3150_CR162","first-page":"787","volume":"73","author":"W Birkmayer","year":"1961","unstructured":"Birkmayer, W. & Hornykiewicz, O. [The L-3, 4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. Wien. Klin. Wochenschr. 73, 787\u2013788 (1961).","journal-title":"Wien. Klin. Wochenschr."},{"key":"BFnrc3150_CR163","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJM196902132800701","volume":"280","author":"GC Cotzias","year":"1969","unstructured":"Cotzias, G. C., Papavasiliou, P. S. & Gellene, R. Modification of Parkinsonism--chronic treatment with L-dopa. N. Engl. J. Med. 280, 337\u2013345 (1969).","journal-title":"N. Engl. J. Med."},{"key":"BFnrc3150_CR164","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/26652","volume":"395","author":"E Leroy","year":"1998","unstructured":"Leroy, E. et al. The ubiquitin pathway in Parkinson's disease. Nature 395, 451\u2013452 (1998).","journal-title":"Nature"},{"key":"BFnrc3150_CR165","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601\u2013607 (2004).","journal-title":"Neuron"},{"key":"BFnrc3150_CR166","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"C Paisan-Ruiz","year":"2004","unstructured":"Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595\u2013600 (2004).","journal-title":"Neuron"},{"key":"BFnrc3150_CR167","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ymgme.2003.11.004","volume":"81","author":"A Lwin","year":"2004","unstructured":"Lwin, A., Orvisky, E., Goker-Alpan, O., LaMarca, M. E. & Sidransky, E. Glucocerebrosidase mutations in subjects with parkinsonism. Mol. Genet. Metab. 81, 70\u201373 (2004).","journal-title":"Mol. Genet. Metab."},{"key":"BFnrc3150_CR168","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1038\/ng1884","volume":"38","author":"A Ramirez","year":"2006","unstructured":"Ramirez, A. et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nature Genet. 38, 1184\u20131191 (2006).","journal-title":"Nature Genet."},{"key":"BFnrc3150_CR169","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(10)62345-8","volume":"377","author":"MA Nalls","year":"2011","unstructured":"Nalls, M. A. et al. Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377, 641\u2013649 (2011).","journal-title":"Lancet"}],"container-title":["Nature Reviews Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrc3150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3150","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrc3150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,14]],"date-time":"2024-04-14T02:14:42Z","timestamp":1713060882000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrc3150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,24]]},"references-count":169,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["BFnrc3150"],"URL":"https:\/\/doi.org\/10.1038\/nrc3150","relation":{},"ISSN":["1474-175X","1474-1768"],"issn-type":[{"value":"1474-175X","type":"print"},{"value":"1474-1768","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,24]]}}}